School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan, Shandong, 250117, China.
Department of Endocrinology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, China.
Endocrine. 2024 Apr;84(1):253-264. doi: 10.1007/s12020-023-03614-1. Epub 2024 Jan 29.
11β-Hydroxylase deficiency (11β-OHD) is the second leading cause of congenital adrenal hyperplasia (CAH), a rare autosomal recessive disease caused by mutations in the CYP11B1 gene. We previously reported the case of a male Chinese patient with typical 11β-OHD symptoms. Sanger sequencing revealed that the patient carried a splice-site mutation, c.595+1G>A in the CYP11B1 gene. His mother and sister harbored the heterozygous mutation, c.595+1G>A. Paradoxically, Sanger sequencing did not detect any abnormality in the CYP11B1 gene of his father and brother. Therefore, in this study, we aimed to further explore the exact genetic etiology of 11β-OHD in this pedigree and analyze the functional consequence of the c.595+1G>A mutation.
Gemomic DNA was extracted from the peripheral blood leukocytes of the family members and normal control individuals, followed by quantitative real-time polymerase chain reaction (qPCR) to detect the copy number of the target CYP11B1 gene fragment. Mutation analysis was also performed via whole-exome sequencing (WES) followed by Sanger sequencing validation. In vitro minigene assay was also performed to investigate the impact of the c.595+1G>A mutation on pre-mRNA splicing.
qPCR results suggested a heterozygous deletion encompassing position c.595+1 along with flanking exonic and intronic sequences in the CYP11B1 gene of the patient and his father. WES followed by Sanger sequencing verified that the patient carried compound heterozygous mutations in the CYP11B1 gene, including a novel 2840-bp deletion (c.395+661_c.1121+180del) and c.595+1G>A, while his father carried the heterozygous c.395+661_c.1121+180del mutation. No other novel CYP11B1 mutations were found in the rest of the family members. Furthermore, minigene assay revealed that the c.595+1G>A mutation resulted in a 70-bp deletion of exon 3 in the mRNA, and this altered the reading frame at amino acid 176 and created a premature stop codon at amino acid 197.
We identified a novel 2840-bp-sized large deletion and confirmed that the c.595+1G>A mutation disrupts normal pre-mRNA splicing. Either mutation could significantly alter the reading frame and abolish CYP11B1 enzyme activity. Therefore, our findings widen the mutation spectrum of CYP11B1 and provide an accurate diagnosis of 11β-OHD at a molecular genetic level.
11β-羟化酶缺乏症(11β-OHD)是先天性肾上腺皮质增生症(CAH)的第二大病因,是一种由 CYP11B1 基因突变引起的罕见常染色体隐性疾病。我们之前报道了一例具有典型 11β-OHD 症状的中国男性患者。Sanger 测序显示,该患者携带 CYP11B1 基因中的剪接位点突变 c.595+1G>A。他的母亲和妹妹携带杂合突变 c.595+1G>A。矛盾的是,Sanger 测序并未检测到其父亲和兄弟的 CYP11B1 基因存在任何异常。因此,在本研究中,我们旨在进一步探讨该家系中 11β-OHD 的确切遗传病因,并分析 c.595+1G>A 突变的功能后果。
从家系成员和正常对照个体的外周血白细胞中提取基因组 DNA,随后进行定量实时聚合酶链反应(qPCR)以检测目标 CYP11B1 基因片段的拷贝数。通过全外显子组测序(WES)进行突变分析,并通过 Sanger 测序验证。还进行了体外迷你基因试验,以研究 c.595+1G>A 突变对前体 mRNA 剪接的影响。
qPCR 结果表明,患者及其父亲的 CYP11B1 基因中存在包含位置 c.595+1 在内的杂合缺失,以及侧翼外显子和内含子序列。WES 结合 Sanger 测序验证了患者携带 CYP11B1 基因的复合杂合突变,包括一个新的 2840-bp 缺失(c.395+661_c.1121+180del)和 c.595+1G>A,而他的父亲携带杂合 c.395+661_c.1121+180del 突变。在其余家庭成员中未发现其他新的 CYP11B1 突变。此外,迷你基因试验表明,c.595+1G>A 突变导致 mRNA 中exon3 缺失 70bp,从而改变了氨基酸 176 处的阅读框,并在氨基酸 197 处产生了一个提前终止密码子。
我们鉴定了一个新的 2840-bp 大小的大片段缺失,并证实 c.595+1G>A 突变破坏了正常的前体 mRNA 剪接。任一突变都可能显著改变阅读框并使 CYP11B1 酶活性丧失。因此,我们的发现拓宽了 CYP11B1 的突变谱,并在分子遗传学水平上提供了 11β-OHD 的准确诊断。